Investigating the effect of melatonin use versus placebo on delirium in patients admitted to the intensive care unit

Status

Active, not recruiting

Phases

Phase 3

Study type

Interventional

Source

IRCT

Registry ID

IRCT20240429061595N1

Enrollment

140

Registered

2024-05-11

Start date

2023-01-21

Completion date

Unknown

Last updated

2024-05-27

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

delirium. Other delirium

Interventions

Intervention 1: Intervention group: group A patients were given 3 mg of melatonin every 22 hours for 4 days (Vitalol produced by Mehban Daru Company). Intervention 2: Control group: group B patients w

Eligibility

Sex/Gender

All

Age

18 Years to No maximum

Inclusion criteria

Inclusion criteria: Age 18 and above written and informed consent from the patient's legal guardian

Exclusion criteria

Exclusion criteria: Allergy to melatonin intestinal obstruction gastroparesis side absorption

Design outcomes

Primary

Measure	Time frame
Occurrence of delirium. Timepoint: 4 days after the intervention. Method of measurement: examination.	—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactMahnaz Narimani Zamanabadi

Islamic Azad University

mahnaznarimani@yahoo.com+98 21 2660 2642

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026